Molecular Involvement and Prognostic Importance of Fms-like Tyrosine Kinase 3 in Acute Myeloid Leukemia

Sadaf Shahab*, Tahir S Shamsi, Nuzhat Ahmed

Abstract

AML (Acute myeloid leukemia) is a form of blood cancer where growth of myeloid cells occurs in the bone marrow. The prognosis is poor in general for many reasons. One is the presence of leukaemia-specific recognition markers such as FLT3 (fms-like tyrosine kinase 3). Another name of FLT3 is stem cell tyrosine kinase-1 (STK1), which is known to take part in proliferation, differentiation and apoptosis of hematopoietic cells, usually being present on haemopoietic progenitor cells in the bone marrow. FLT3 act as an independent prognostic factor for AML. Although a vast literature is available about the association of FLT3 with AML there still is a need of a brief up to date overview which draw a clear picture about this association and their effect on overall survival.

Keywords: AML - FLT3 - ITDs - (TKD) - leukemia-specific recognition markers - prognostic marker

Introduction

Leukemia is a type of blood cancer where immature hematopoietic cells propagate in an abandoned manner. Bone marrow is the origin of Leukemia and there after it spreads rapidly anywhere (Islam, 1992). There are four main types of Leukemia, Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Chronic Myeloid Leukemia(CML) and Chronic Lymphocytic Leukemia(ALL). Acute Myeloid Leukemia (AML) is a blood cancer where abandoned growth of immature myeloid cells (myeloblasts, promyelocytes, monoblasts, erythroblasts, megakaryoblasts) in the bone marrow reduces the number of platelets, white blood cells and red blood cells.

AML is classified into four subtypes depending upon their stage of maturation and differentiation, which are: Acute Myeloid Leukemia with maturation, Acute Promyelocytic Leukemia (APL), Acute Erythroleukemia, Acute Myelomonocytic Leukemia, Acute Monocytic/Monoblastic Leukemia, Acute Megakaryoblastic Leukemia and Acute Myeloid Leukemia without maturation (Warner et al., 2005; Li and Amit, 2009).

Acquired mutations in AML, interrupt the typical process of differentiation in the blood-forming cells, which results in the accumulation of large numbers of immature cells or myeloblasts. In case, erythroid lineage is affected, it can not perform the full functions of typical healthy red blood cells and creates anemic condition (Warner et al., 2005).

The molecular classification of AML was initiated and role of independent prognostic markers in AML was started gaining popularity about two decades back (Bloomfield et al., 1984). The study of some of these markers has provided knowledge and understanding of disease pathogenesis and their biological and clinical outcomes. This approach has now been included into the classification of haemopoietic and lymphoid neoplasms of recent World Health Organization (WHO). The cytogenetic categories and risk groups are added in the 4th edition of the WHO guidelines. Patients are classified according to their cytogenetics into three different risk groups. This group include poor/worsen response group, favourable response group and standard/intermediate group (Elias et al., 2011).

The unplanned high dose chemo therapy is now restricted and molecular prognostics markers and cytogenetics become the main basis to develop a more risk free disease stratification plan. The main beneficiaries of this approach are inv(16), t(15;17) and t(8;21) (David et al., 2010).

Grimwade et al. (1998) reported that patients included in bad risk group disease have worsen or inferior survival rate because of partial/complete loss of genetic material. Such abnormalities create an unfavorable response to targeted therapy. Approximately 50% of patients have standard risk groupe; but their increased relapse rate is the main obstacle (David et al., 2010). Although some of these patients have abnormal karyotype, but about half of patients, have a normal karyotype (Richard et al., 2008; David et al., 2010). Therefore it is prerequisite to identify focal leukemic markers which help in deciding the route of treatment for the patients.

In this review we try to update the prognostic
involvement of FLT3 mutations on overall survival, remission and relapse.

What We Already Know about Fms-like Tyrosine Kinase

Fetal liver tyrosine kinase-2 (FLK-2) or FLT3 (fms-like tyrosine kinase 3) or (STK1) (stem cell tyrosine kinase-1 is actually a member of the class III tyrosine-kinase receptor-family (RTK) which helps in apoptosis of hematopoietic cells and their proliferation (Yeo et al., 2010). It is the single most common mutated genes in AML and chiefly expressed by early myeloid and lymphoid progenitor cells (Rosnet et al., 1993), and also present on placenta, brain, cerebellum and gonads (Maroc et al., 1993; Frascella et al., 2006). The gene of FLT3 consists of 24 exons and is localized on chromosome 13q12 (Birg et al., 1994; Shurin et al., 1998; Abu et al., 2001). Approximately 5-15% of children and 25-35% of adults exhibit FLT3 mutation (Stirewalt and Radich, 2003; Schinichiro, 2011). A vast variety of literature considered FLT3 as bad prognostic marker (David et al., 2010; Patrick et al., 2011).

What are the Biological Consequences of FLT3?

Internal tandem duplications (ITDs) is the first FLT3 mutations encoded by exons 14 and 15 which was identified unexpectedly (Nakao et al., 1996). Unpredictably lengthy segments of DNA were noticed in the PCR products of five AML patients. The isolation of genomic DNA from same patient, ruled out the alternate splicing. Additional studies confirmed that they all have duplicated sequences. These duplicated regions may contain insertion of additional nucleotides. Size and location of the duplicated region may vary person to person but always cause in frame mutation (Yokata et al., 1997).

Frequency of FLT3/ITD in Patients and Healthy Individuals

The over expression of FLT3 mRNA is the main culprit in AML patients (David et al., 2010). FLT3/ITDs are the single most frequent mutation present in AML patients Schnichiro (2011). The over all frequency of ITD was 24% (Gale, 2003; Murphy et al., 2003) although few studies reported as high as 38 % and 44% (Govedarovic, 2011). Their prevalence in myelodysplastic syndromes (MDS) is 3% (Horiike et al., 1997) while occasional in patients of ALL (Nakao et al., 1996; Yokata et al., 1997). Although Yokata et al. (1997) has reported independently discovered point mutations in exon 20, in the TK domain. The overall frequency of TKD mutations reported is 7.1%. These mutations mostly codes for histidine and tyrosine. The insertion of few nucleotides or complete deletion of I836, have also been reported, but these mutations are always in frame.

Yamamoto et al. (2001) and Abu-Duhier et al. (2001b) independently discovered point mutations in exon 20, in the TK domain. The overall frequency of TKD mutations reported is 7.1%. These mutations mostly codes for histidine and tyrosine. The insertion of few nucleotides or complete deletion of I836, have also been reported, but these mutations are always in frame.

Yamamoto et al. (2001) reported occasional cases in MDS is (3.4%) and 2.8% in ALL. The mutation causes constitututive tyrosine phosphorylation which result in gain of function (Yamamoto et al., 2001; Gale, 2003). The effect of TKD mutations are more or less similar to FLT3/ITD mutations which result in disturbance of auto inhibitory mechanism that prevent cells from uncontrolled signaling. More while few authors also reported the addition of 6 bp nucleotides which insert amino acids glycine and serine between codon 840 and 841 in 0.5% AML patients (Spiekermann et al., 2002; Gale 2003).

Biological Features of FLT3/ITD Mutations in AML Patients

Many studies suggested that the activating mutations of receptor tyrosine kinases (RTKs) and over expression are chiefly involved in pathogenesis. (Gu et al., 2011). Approximately 25-30% of patients are ITD positive (Kottaridis et al., 2001; Schnittger et al., 2002; Thiede et al., 2002). ITD are always in frame mutations but may varies in length.

The frequency of FLT3/ITD mutations is low in patients having favorable cytogenetics i.e inv (16) (0-
Table 1. Clinical and Pathological Characteristics of the AML Cases in this Study

<table>
<thead>
<tr>
<th>Study</th>
<th>No.of patients</th>
<th>Pediatric AML</th>
<th>Adult AML</th>
<th>Norm/Intr Cytogenetics (a)</th>
<th>8;21 or INV16</th>
<th>Poor risk Cyto (b)</th>
<th>Secondary AML (c)</th>
<th>Elderly AML (d)</th>
<th>Survival</th>
</tr>
</thead>
<tbody>
<tr>
<td>Horiike et al</td>
<td>30</td>
<td></td>
<td></td>
<td></td>
<td>14.70%</td>
<td>(5/34)</td>
<td></td>
<td></td>
<td>ND</td>
</tr>
<tr>
<td>Kiyoi et al</td>
<td>74</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Decreased</td>
</tr>
<tr>
<td>Yamamoto et al</td>
<td>429</td>
<td></td>
<td></td>
<td>18.90% (81/429)</td>
<td>28.00%</td>
<td>(23/82)</td>
<td>11.80%</td>
<td>(4/34)</td>
<td>Decreased</td>
</tr>
<tr>
<td>Rombouts et al</td>
<td>75</td>
<td></td>
<td></td>
<td>23.70% (14/59)</td>
<td></td>
<td>0</td>
<td></td>
<td>(0/6)</td>
<td>Decreased</td>
</tr>
<tr>
<td>Abu-Duhier et al</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>22.70%</td>
<td>(10/44)</td>
<td>5.80%</td>
<td>(3/52)</td>
<td>Decreased</td>
</tr>
<tr>
<td>Stirewalt</td>
<td>140</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>28.00%</td>
<td></td>
<td>(23/82)</td>
<td>No Effect</td>
</tr>
<tr>
<td>Kottaridis et al</td>
<td>854</td>
<td></td>
<td></td>
<td></td>
<td>36.80%</td>
<td>(49/133)</td>
<td>34.20%</td>
<td>(96/281)</td>
<td>Decreased</td>
</tr>
<tr>
<td>Whitman et al</td>
<td>82</td>
<td></td>
<td></td>
<td></td>
<td>33.60%</td>
<td>(47/140)</td>
<td>8.30%</td>
<td>(5/147)</td>
<td>No Effect</td>
</tr>
<tr>
<td>Iwai et al</td>
<td>94</td>
<td></td>
<td></td>
<td>5.30% (5/94)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Decreased</td>
</tr>
<tr>
<td>Xu et al</td>
<td>87</td>
<td></td>
<td></td>
<td>13.80% (12/87)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Decreased</td>
</tr>
<tr>
<td>Kondo et al</td>
<td>64</td>
<td></td>
<td></td>
<td>10.90% (7/64)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Decreased</td>
</tr>
<tr>
<td>Meshinchi et al</td>
<td>91</td>
<td></td>
<td></td>
<td>16.50% (15/91)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Decreased</td>
</tr>
<tr>
<td>Lian et al</td>
<td>80</td>
<td></td>
<td></td>
<td>11.30% (9/88)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Decreased</td>
</tr>
<tr>
<td>Thiede et al</td>
<td>979</td>
<td></td>
<td></td>
<td>22.20% (217/979)</td>
<td>29.70%</td>
<td>(134/451)</td>
<td>4.50%</td>
<td>(4/88)</td>
<td>Decreased</td>
</tr>
<tr>
<td>Schnittger et al</td>
<td>1003</td>
<td></td>
<td></td>
<td>23.30% (234/1003)</td>
<td>39.30%</td>
<td>(149/379)</td>
<td>5.40%</td>
<td>(6/11)</td>
<td>No Effect</td>
</tr>
<tr>
<td>Boissel et al</td>
<td>159</td>
<td></td>
<td></td>
<td>25.20% (40/159)</td>
<td>35.40%</td>
<td>(28/79)</td>
<td>0</td>
<td>(0/23)</td>
<td>No Effect</td>
</tr>
<tr>
<td>Noguera et al</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>No Effect</td>
</tr>
<tr>
<td>Frohling et al</td>
<td>523</td>
<td></td>
<td></td>
<td>22.80% (119/523)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Decreased</td>
</tr>
<tr>
<td>Kainz et al</td>
<td>100</td>
<td></td>
<td></td>
<td>30.20% (16/53)</td>
<td></td>
<td>7.70%</td>
<td>(2/26)</td>
<td></td>
<td>Decreased</td>
</tr>
<tr>
<td>Moreno et al</td>
<td>208</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>0%</td>
<td>(0/14)</td>
<td></td>
<td>Decreased</td>
</tr>
<tr>
<td>Jilani et al</td>
<td>85</td>
<td></td>
<td></td>
<td>21.20% (18/85)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Decreased</td>
</tr>
<tr>
<td>Arrigoni et al</td>
<td>45</td>
<td></td>
<td></td>
<td>22.20% (10/45)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Decreased</td>
</tr>
<tr>
<td>Zwan</td>
<td>234</td>
<td></td>
<td></td>
<td>11.50% (27/234)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Decreased</td>
</tr>
<tr>
<td>Xu</td>
<td>103</td>
<td></td>
<td></td>
<td>23.20% (22/103)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>RR is 66.8%</td>
</tr>
<tr>
<td>Natasa</td>
<td>113</td>
<td></td>
<td></td>
<td>17.70% (20/113)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>-1</td>
</tr>
<tr>
<td>Wang</td>
<td>76</td>
<td></td>
<td></td>
<td>19.70% (15/76)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Decreased</td>
</tr>
<tr>
<td>Dohner</td>
<td>300</td>
<td></td>
<td></td>
<td>12.7% imNPM wt 19.7% in NPM mut</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Decreased</td>
</tr>
<tr>
<td>Peerddeep</td>
<td>133</td>
<td></td>
<td></td>
<td>20%</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>No Effect</td>
</tr>
<tr>
<td>Rababab Aly</td>
<td>39</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Decreased</td>
</tr>
<tr>
<td>Govedarovic and Marjanovic</td>
<td>103</td>
<td></td>
<td></td>
<td>44.7%</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Decreased</td>
</tr>
<tr>
<td>Schlenk et al</td>
<td>531</td>
<td></td>
<td></td>
<td>31% (164/531)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Decreased</td>
</tr>
</tbody>
</table>

DOI:http://dx.doi.org/10.7314/APJCP.2012.13.8.4215

Prognostic Involvement of FLT3 in Acute Myeloid Leukemia
for ITD positive patients (Table 1). One important factor survival and disease-free survival are significantly lower (Kottaridis, 2001; Mesinchi et al., 2001; Frohling et al., 2002; Rosemary et al., 2008). It has been reported that overall survival and disease-free survival are significantly lower for ITD positive patients (Table 1). One important factor which should not be overlooked is the ratio between FLT3 wild type allele and FLT3 mutant allele. The FLT3-ITD load, loss of heterozygosity or loss of wild type allele as it usually result in lower over all survival and Disease free survival. (Schnittger et al., 2002; Schneider et al., 2011).

Conclusion

Many studies have shown that ITD mutations have clear relationship with the prognosis and clinical response in AML. The data shown in Table 1 clearly suggests that FLT3/ITD result in the over all poor prognosis. AML patients with FLT3/ITD mutation had an obviously increased expression level of FLT3/ITD upon relapsed proposed that FLT3/ITD might involved in constitutive stimulation and proliferation of residual blast cell. The identification of FLT3 mutations might be an important step for optimization of patient care. Because FLT3 ITD mutations portend a worsen prognosis, it has been proposed that patients who are FLT3/ITD positive may benefit from an allogeneic bone marrow transplantation instead of aggressive chemotherapy.

References

significance of activating FLT3 mutations in younger adults (16-60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm. Blood, 100, 4372-0.


DOI:http://dx.doi.org/10.7314/APJCP.2012.13.8.4215

Prognostic Involvement of FLT3 in Acute Myeloid Leukemia


